Ramon L Varcoe, Brian G DeRubertis, Raghu Kolluri, Prakash Krishnan, David C Metzger, Marc P Bonaca, Mehdi H Shishehbor, Andrew H Holden, Danielle R Bajakian, Lawrence A Garcia, Steven W C Kum, John Rundback, Ehrin Armstrong, Jen-Kuang Lee, Yazan Khatib, Ido Weinberg, Hector M Garcia-Garcia, Karine Ruster, Nutte T Teraphongphom, Yan Zheng, Jin Wang, Jennifer M Jones-McMeans, Sahil A Parikh
BACKGROUND: Among patients with chronic limb-threatening ischemia (CLTI) and infrapopliteal artery disease, angioplasty has been associated with frequent reintervention and adverse limb outcomes from restenosis. The effect of the use of drug-eluting resorbable scaffolds on these outcomes remains unknown. METHODS: In this multicenter, randomized, controlled trial, 261 patients with CLTI and infrapopliteal artery disease were randomly assigned in a 2:1 ratio to receive treatment with an everolimus-eluting resorbable scaffold or angioplasty...
January 4, 2024: New England Journal of Medicine